Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions initial findings

Bernard A. Birnbaum, Jeffrey C. Weinreb, Maria P. Fernandez, Jeffrey J. Brown, Neil M. Rofsky, Stuart W. Young

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Twenty-nine patients with known or suspected focal hepatic disease were evaluated in a retrospective multiinstitutional study comparing TI-weighted manganese (II) NM-dipyridoxylethylenediamine-NM-diacetate 5,5'-bis (phosphate) (DPDP) enhanced magnetic resonance imaging (MRI) with dynamic sequential bolus contrast enhanced computed tomography (DBCT) for the detection of focal liver lesions. The patients were divided into four dose groups, receiving 3, 5, 8, or 10 μmol/kg of Mn-DPDP, delivered either via intravenous bolus (0.25 ml/sec) or infusion (1 ml/sec). Each of three readers, with varying levels of expertise in interpreting hepatic MRI and CT studies, identified more lesions on the Mn-DPDP enhanced MRI than the contrast enhanced CT images. Mn-DPDP enhanced MRI depicted the presence of extensive metastatic disease not seen with DBCT in three patients with fatty liver. The most experienced MRI reader saw more lesions per patient on the Mn-DPDP enhanced MRI than with DBCT, while the opposite held true for the most experienced CT reader. The best single exam for detection of hepatic lesions may be determined by the experience of the reader.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalClinical Imaging
Issue number1
StatePublished - 1994


  • Computed Tomography
  • Contrast enhancement
  • Liver
  • Magnetic resonance imaging
  • Manganese

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions initial findings'. Together they form a unique fingerprint.

Cite this